Investigating the role of specific proteins in patients with alpha-1 antitrypsin deficiency
Official title: Leukotriene B4 and IL-8 in alpha-1 heterozygotes (PI*MZ genotype)
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11052518 · Data updated 2026-11-12
This study is looking at how a specific genetic variant affects lung health in people with alpha-1 antitrypsin deficiency, and it's inviting individuals with the PI*MZ genotype to share their samples and experiences to help improve understanding and treatment of the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $170,542 |
| NIH project number | 5K23HL173570-02 |
| Project ID | NIH-11052518 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with alpha-1 antitrypsin deficiency who carry the PI*MZ genotype.
✕Less likely to help
Patients without alpha-1 antitrypsin deficiency or those with different genotypes may not benefit from this research.
What this research studies
This research focuses on understanding the differences in disease presentation among individuals with a specific genetic variant related to alpha-1 antitrypsin deficiency. The study involves recruiting participants who carry the PI*MZ genotype and analyzing their genetic and biological samples to explore how these factors influence airway inflammation and overall lung health. Patients will be actively involved in providing biospecimens and participating in assessments that will help researchers gain insights into the condition. The research aims to enhance knowledge about the disease and improve future treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to better-targeted therapies and management strategies for patients with alpha-1 antitrypsin deficiency.
How similar studies have gone: Previous research has shown promise in understanding genetic factors in alpha-1 antitrypsin deficiency, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Tejwani, Vickram — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Tejwani, Vickram
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.